New cancer clinical trial: Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

Published on: August 16, 2018 at 12:00PM
Conditions:   Estrogen Receptor-positive Breast Cancer;   HER2/Neu Negative;   Stage IV Breast Cancer AJCC v6 and v7
Interventions:   Drug: Palbociclib;   Drug: Letrozole;   Drug: Fulvestrant;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment
Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
Recruiting
https://ift.tt/2PgJr1K